Taipei Exchange - Delayed Quote TWD

Taiwan Bio Therapeutics Co., Ltd (6892.TWO)

34.55
+1.05
+(3.13%)
As of 1:00:05 PM GMT+8. Market Open.
Loading Chart for 6892.TWO
  • Previous Close 33.50
  • Open 33.75
  • Bid 34.30 x --
  • Ask 35.00 x --
  • Day's Range 33.00 - 34.80
  • 52 Week Range 27.40 - 60.10
  • Volume 181,233
  • Avg. Volume 91,134
  • Market Cap (intraday) 2.919B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.73
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.

www.twbio-thera.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: 6892.TWO

View More

Performance Overview: 6892.TWO

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6892.TWO
15.73%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
3.93%

1-Year Return

6892.TWO
8.60%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.82%

3-Year Return

6892.TWO
20.22%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.70%

5-Year Return

6892.TWO
20.22%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
93.61%

Compare To: 6892.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6892.TWO

View More

Valuation Measures

Annual
As of 6/12/2025
  • Market Cap

    2.80B

  • Enterprise Value

    2.55B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    25.87

  • Price/Book (mrq)

    2.75

  • Enterprise Value/Revenue

    25.30

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -4.73

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 6892.TWO

View More

Company Insights: 6892.TWO

Research Reports: 6892.TWO

View More